Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

Asieris Pharmaceuticals licenses CEVIRA cervical treatment to Theramex for Europe and other markets

Asieris Pharmaceuticals has entered an exclusive licensing agreement with Theramex for CEVIRA (APL-1702), a first-in-class non-surgical treatment for cervical precancerous lesions, granting Theramex rights in Europe, Australia, New Zealand and Turkey. The deal includes $15 million upfront, $11 million in near-term regulatory milestones, plus commercial milestones and tiered royalties.